Literature DB >> 25771832

Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review.

Catherine Terret1, Gilles Albrand, Muriel Rainfray, Pierre Soubeyran.   

Abstract

Treating non-Hodgkin's lymphoma in patients with comorbidities can be challenging because of possible interactions that may alter the treatment efficacy. We conducted a systematic review to determine the impact of comorbidities on various outcomes, evaluate the current data, and provide recommendations for future research. Twenty-one articles were selected. However, the study populations and design were greatly heterogeneous, and the quality of reporting was generally weak. The majority of studies demonstrated significant impact of comorbidity on survival, reporting poorer survival rates for patients with comorbidities compared to those with no comorbidities. However, the existing evidence is limited and of insufficient quality to establish solid conclusions and to guide treatment decisions. Prospective, well-designed studies are warranted.

Entities:  

Keywords:  chemotherapy; comorbidity; diffuse large B-cell lymphoma; geriatric assessment; malignant lymphoma; non-Hodgkin’s lymphoma

Mesh:

Substances:

Year:  2015        PMID: 25771832     DOI: 10.1586/17474086.2015.1024650

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  2 in total

1.  Survival and glycemic control in patients with coexisting lymphoma and diabetes: a case-control analysis.

Authors:  Bria J Rice; Matthew R Buras; Heidi E Kosiorek; Kyle E Coppola; Shailja B Amin; Patricia M Verona; Curtiss B Cook; Nina J Karlin
Journal:  Future Sci OA       Date:  2020-10-27

2.  Association between multimorbidity and socioeconomic deprivation on short-term mortality among patients with diffuse large B-cell or follicular lymphoma in England: a nationwide cohort study.

Authors:  Matthew James Smith; Edmund Njeru Njagi; Aurelien Belot; Clémence Leyrat; Audrey Bonaventure; Sara Benitez Majano; Bernard Rachet; Miguel Angel Luque Fernandez
Journal:  BMJ Open       Date:  2021-11-30       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.